[go: up one dir, main page]

WO1999022720A3 - Procede d'utilisation d'inhibiteurs de cyclooxygenase-2 dans le maintien du canal arteriel foetal au cours du traitement et de la prevention du travail preterme - Google Patents

Procede d'utilisation d'inhibiteurs de cyclooxygenase-2 dans le maintien du canal arteriel foetal au cours du traitement et de la prevention du travail preterme Download PDF

Info

Publication number
WO1999022720A3
WO1999022720A3 PCT/US1998/022246 US9822246W WO9922720A3 WO 1999022720 A3 WO1999022720 A3 WO 1999022720A3 US 9822246 W US9822246 W US 9822246W WO 9922720 A3 WO9922720 A3 WO 9922720A3
Authority
WO
WIPO (PCT)
Prior art keywords
selective cyclooxygenase
premature labor
inhibitors against
against premature
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/022246
Other languages
English (en)
Other versions
WO1999022720A2 (fr
Inventor
Philip Needleman
Jaime Masferrer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Priority to CA002308639A priority Critical patent/CA2308639A1/fr
Priority to JP2000518654A priority patent/JP2001521889A/ja
Priority to EP98955026A priority patent/EP1027048A2/fr
Priority to BR9813164-8A priority patent/BR9813164A/pt
Priority to AU11926/99A priority patent/AU758566B2/en
Publication of WO1999022720A2 publication Critical patent/WO1999022720A2/fr
Publication of WO1999022720A3 publication Critical patent/WO1999022720A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Cette invention porte sur l'utilisation d'inhibiteurs de cyclooxygénase-2 ou de dérivés de celle-ci dans la prévention et le traitement du travail préterme. Cette invention porte notamment sur un procédé de prévention et de traitement du travail préterme chez une patiente, ce procédé consistant à traiter la patiente avec une quantité thérapeutiquement efficace d'un composé de la formule (I) dans laquelle R?1, R2 et R3¿ sont tels que décrits dans la demande.
PCT/US1998/022246 1997-10-31 1998-10-27 Procede d'utilisation d'inhibiteurs de cyclooxygenase-2 dans le maintien du canal arteriel foetal au cours du traitement et de la prevention du travail preterme Ceased WO1999022720A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002308639A CA2308639A1 (fr) 1997-10-31 1998-10-27 Methode pour l'utilisation d'inhibiteurs de cyclooxygenase-2 permettant de maintenir le canal arteriel foetal au cours du traitement et de la prevention d'accouchements prematures
JP2000518654A JP2001521889A (ja) 1997-10-31 1998-10-27 早期分娩の治療及び予防中における胎児動脈管の維持にシクロオキシゲナーゼ−２阻害剤を使用する方法
EP98955026A EP1027048A2 (fr) 1997-10-31 1998-10-27 Procede d'utilisation d'inhibiteurs de cyclooxygenase-2 dans le maintien du canal arteriel foetal au cours du traitement et de la prevention du travail preterme
BR9813164-8A BR9813164A (pt) 1997-10-31 1998-10-27 Método de uso de inibidores da ciclooxigenase-2 na manutenção do ducto arterial fetal durante o tratamento e prevenção de dores prematuras de parto
AU11926/99A AU758566B2 (en) 1997-10-31 1998-10-27 Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6388997P 1997-10-31 1997-10-31
US60/063,889 1997-10-31

Publications (2)

Publication Number Publication Date
WO1999022720A2 WO1999022720A2 (fr) 1999-05-14
WO1999022720A3 true WO1999022720A3 (fr) 1999-08-26

Family

ID=22052179

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/022246 Ceased WO1999022720A2 (fr) 1997-10-31 1998-10-27 Procede d'utilisation d'inhibiteurs de cyclooxygenase-2 dans le maintien du canal arteriel foetal au cours du traitement et de la prevention du travail preterme

Country Status (9)

Country Link
EP (1) EP1027048A2 (fr)
JP (1) JP2001521889A (fr)
AR (1) AR014000A1 (fr)
AU (1) AU758566B2 (fr)
BR (1) BR9813164A (fr)
CA (1) CA2308639A1 (fr)
TW (2) TW577739B (fr)
WO (1) WO1999022720A2 (fr)
ZA (1) ZA989876B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152792A0 (en) * 2000-06-08 2003-06-24 Univ Texas Heterocycle derivatives and methods of use
ATE342722T1 (de) 2003-05-07 2006-11-15 Osteologix As Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521207A (en) * 1993-11-30 1996-05-28 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamide for the treatment of inflammation
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026731A1 (fr) * 1993-05-13 1994-11-24 Merck Frosst Canada Inc. Inhibiteurs de la cyclogenase
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
WO1997031631A1 (fr) * 1996-02-27 1997-09-04 Rpms Technology Limited Inhibiteurs selectifs de cox-2 destines a la maitrise de la periode de travail et des contractions uterines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521207A (en) * 1993-11-30 1996-05-28 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamide for the treatment of inflammation
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BOTTING: "COX-2 : selective inhibitors in clinical trials", DRUG NEWS AND PERSPECTIVES, vol. 9, no. 2, 1996, pages 123 - 128, XP002104738 *
DATABASE EMBASE ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; XP002104739 *
KATORI ET AL.: "Multiple roles of inducible cyclooxygenase-2 and its selective inhibitors", FOLIA PHARMACOLOGICA JAPONICA, vol. 109, no. 6, 1 June 1997 (1997-06-01), pages 247 - 258 *
SMITH: "The pharmacology of the ductus arteriosus", PHARMACOL. REVIEWS, vol. 50, no. 1, 1 March 1998 (1998-03-01), pages 35 - 50, XP002104737 *
VANE ET AL.: "Cyclooxygenases 1 and 2", ANN. REV. PHARMOCOL. TOXICOL., vol. 38, 1 January 1998 (1998-01-01), pages 97 - 120, XP002074177 *
VANE ET AL.: "Mechanism of action of antiinflammatory drugs", INT. J. TISSUE REACT., vol. 20, no. 1, January 1998 (1998-01-01), pages 3 - 15, XP002104736 *
VANE ET AL.: "Mechanism of action of aspirin-like drugs", SEMIN. ARTHRITIS RHEUM., vol. 26, no. 6sup1, June 1997 (1997-06-01), pages 2 - 10, XP002104735 *

Also Published As

Publication number Publication date
EP1027048A2 (fr) 2000-08-16
AU1192699A (en) 1999-05-24
ZA989876B (en) 1999-10-29
CA2308639A1 (fr) 1999-05-14
TW200404535A (en) 2004-04-01
BR9813164A (pt) 2000-08-22
JP2001521889A (ja) 2001-11-13
AR014000A1 (es) 2001-01-31
WO1999022720A2 (fr) 1999-05-14
TW577739B (en) 2004-03-01
AU758566B2 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
WO1999004752A3 (fr) Procede pour le traitement de la pigmentation de la peau
CA2258606A1 (fr) Forme cristalline ii de la clarithromycine
WO2004019791A3 (fr) Dispositif d'occlusion d'une anomalie vasculaire, et methode de traitement associee
CA2201123A1 (fr) Procede epilatoire
WO2002098444A3 (fr) Utilisation de l'hepcidine comme regulateur de l'homeostasie ferrique
AU2001262723A1 (en) 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
DK1066056T4 (da) Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernmangel, fremgangsmåde til fremstilling af jerndextranforbindelsen og anvendelse af denne forbindelse til fremstilling af et...
EP0846464A3 (fr) Utilisation d'inhibiteur de la glycogen phosphorylase pour réduire les dommages tissulaires non-cardique résultant d'une ischémie
EP0690044A3 (fr) Procédé pour la préparation d'acide amidoéthercarboxylique ou de son sel et mélange d'agent de surface le contenant
WO2002034201A3 (fr) Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique
WO1998036730A3 (fr) Compositions de traitement de l'acne rosacee
WO2002028434A3 (fr) Medicaments
EP0943311A3 (fr) Méthode por inhiber la croissance du poil
WO1999022720A3 (fr) Procede d'utilisation d'inhibiteurs de cyclooxygenase-2 dans le maintien du canal arteriel foetal au cours du traitement et de la prevention du travail preterme
HUP0103754A3 (en) Crystal of diuridine tetraphosphate or salt thereof and method for preparing the same, and method for producing said compound
WO2001041709A3 (fr) Methodes de traitement de maladie et d'inflammation liees a la mort de cellule
WO2005042718A3 (fr) Compositions et methodes permettant de traiter, de prevenir, d'inverser et d'inhiber la douleur
AU6502194A (en) Oestriol-containing hormonal agent for the prophylaxis and treatment of arterial conditions in humans, method of preparing it and its use
WO2000037067A3 (fr) Traitement de lesions cutanees
CA2149209A1 (fr) Utilisation du facteur xiii en application topique pour endiguer les hemorragies
WO1999066780A3 (fr) Nouveaux composes
AU5868699A (en) Novel therapeutic use of compounds with beta-3-agonist activity
WO2002005796A3 (fr) Methode de traitement de l'infection
CA2372912A1 (fr) Application d'inhibiteurs de la cyclogenase-2 au traitement et a la prevention du processus neoplasique
WO2002089779A3 (fr) Preparation combinee pour prevenir et/ou soigner des endommagements de cellules nerveuses et/ou gliales au moyen d'une nouvelle methode de traitement

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 11926/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2308639

Country of ref document: CA

Ref document number: 2308639

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 518654

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998955026

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/A/2000/004204

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1998955026

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 11926/99

Country of ref document: AU